

THE AMERICAN JOURNAL OF MANAGED CARE®

Publishing Staff

Senior Vice President of Operations
and Clinical Affairs

Jeff D. Prescott, PharmD, RPh

Senior Clinical Projects Manager

Ida Delmendo

Clinical Projects Manager

Tara Petersen

Project Director

Christina Doong

Quality Assurance Editor

David Allikas

Associate Editor

Jeanne Linke

Design Director

Charles Lebeda

Director of Sales

Andrew Colon

National Accounts Manager

Sara Stewart

National Accounts Representatives

Gabrielle Consola

John Quinn

Corporate

Chairman and CEO

Mike Hennessy

Vice Chairman

Jack Lepping

President

Tighe Blazier

Chief Financial Officer

Neil Glasser, CPA/CFE

Executive Vice President
and General Manager

John Maglione

President, Managed Markets

Brian Haug

Vice President, Executive Creative
Director

Jeff Brown

Vice President of Human Resources

Rich Weisman

Vice President of Education

David Heckard

Copyright © 2014 by Managed Care
& Healthcare Communications, LLC

October 2014 – Vol. 20, No. 10, Sup.

Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

Table of Contents

Participating Faculty **S202**

Report

■ **Cost Efficiency of Canagliflozin Versus
Sitagliptin for Type 2 Diabetes Mellitus** **S204**

**Varun U. Ektare, BPharm, MPH; Janice M. S. Lopez, PharmD, MPH;
Silas C. Martin, MS; Dipen A. Patel, BPharm, PhD;
Marcia F. T. Rupnow, PhD; Marc F. Botteman, MSc, MA**



MH

A Supplement to *The American Journal of Managed Care*

www.ajmc.com

PROJ A515

Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

This supplement was sponsored by **Janssen Pharmaceuticals, Inc.**

This analysis was funded, in part, by Janssen Scientific Affairs, LLC, and was based on data from a study supported by Janssen Research & Development, LLC. Editorial support was provided by Cherie Koch, PhD, of MedErgy, and was funded by Janssen Scientific Affairs, LLC.

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.

Cost Efficiency of Canagliflozin Versus Sitagliptin for Type 2 Diabetes Mellitus

This supplement to *The American Journal of Managed Care* describes the use of an economic model to compare the cost efficiency of treating type 2 diabetes mellitus with canagliflozin 300 mg versus sitagliptin 100 mg. The modeled clinical and economic outcomes analyses provide information to managed care decision makers in the absence of real-world effectiveness and cost outcomes data. The analyses focused on the achievement of short-term goals that are consistent with recognized diabetes quality metrics, and the results may be useful in aligning reimbursement and best clinical practices.

■ Faculty

Marc F. Botteman, MSc, MA

Partner
Pharmerit International
Bethesda, Maryland

Varun U. Ektare, BPharm, MPH

Lead Outcomes Research Analyst
Pharmerit International
Bethesda, Maryland

Janice M. S. Lopez, PharmD, MPH

Associate Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Raritan, New Jersey

Silas C. Martin, MS

Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Raritan, New Jersey

Dipen A. Patel, BPharm, PhD

Director
HEOR
Pharmerit International
Bethesda, Maryland

Marcia F. T. Rupnow, PhD

Senior Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Raritan, New Jersey

■ Faculty Disclosures

These faculty report relationships with the following organizations:

Marc F. Botteman, MSc, MA

Stock ownership:
Pharmerit International

Janice M. S. Lopez, PharmD, MPH

Employment:
Janssen Scientific Affairs, LLC (a Johnson & Johnson company)
Stock/shareholder:
Johnson & Johnson

■ PARTICIPATING FACULTY ■

Silas C. Martin, MS

Employment:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Marcia F. T. Rupnow, PhD

Employment and meeting/conference attendance:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Varun U. Ektare, BPharm, MPH; and **Dipen A. Patel, BPharm, PhD,** report no relationships or financial interests with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.